Dr Lawrence Jay Goren, MD | |
4607 Oakwood Ln, Nazareth, PA 18064-8535 | |
(610) 837-4683 | |
(610) 837-4975 |
Full Name | Dr Lawrence Jay Goren |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 4607 Oakwood Ln, Nazareth, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861616484 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | MD024453E (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence Jay Goren, MD Po Box D, Bath, PA 18014-0166 Ph: (610) 837-4683 | Dr Lawrence Jay Goren, MD 4607 Oakwood Ln, Nazareth, PA 18064-8535 Ph: (610) 837-4683 |
News Archive
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have studied for the first time the response of human NK cells (Natural Killer) against porcine chondrocytes (cartilage cells).
The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.
In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to cause a flu-like infection in people living in Wuhan, China.
A recent study by researchers in Canada shows how mutations in newly emerging lineages of SARS-CoV-2 may disrupt the sequencing process and thus interfere with this important area of research.
Actavis, Inc. today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Propofol Injection 10mg/mL.
› Verified 5 days ago